ZakAria is a humanized monoclonal antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.ZakAria® (Pembrolizumab) is used alone or in combination with other medicines to treat certain types of cancer including:
